Cargando…
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Most targeted cancer therapies fail to achieve complete tumor regressions or attain durable remissions. To understand why these treatments fail to induce robust cytotoxic responses despite appropriately targeting oncogenic drivers, here we systematically interrogated the dependence of cancer cells o...
Autores principales: | Montero, Joan, Gstalder, Cécile, Kim, Daniel J., Sadowicz, Dorota, Miles, Wayne, Manos, Michael, Cidado, Justin R., Paul Secrist, J., Tron, Adriana E., Flaherty, Keith, Stephen Hodi, F., Yoon, Charles H., Letai, Anthony, Fisher, David E., Haq, Rizwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856172/ https://www.ncbi.nlm.nih.gov/pubmed/31727958 http://dx.doi.org/10.1038/s41467-019-12477-y |
Ejemplares similares
-
Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
por: Dengler, M A, et al.
Publicado: (2014) -
Destabilization of TNF-α mRNA by Rapamycin
por: Park, Jong-Woo, et al.
Publicado: (2012) -
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
por: Montero, Joan, et al.
Publicado: (2022) -
Why do BCL-2 inhibitors work and where should we use them in the clinic?
por: Montero, Joan, et al.
Publicado: (2018) -
A Very Late Viral Protein Triggers the Lytic Release of SV40
por: Daniels, Robert, et al.
Publicado: (2007)